Back to Search
Start Over
[Phase 3 multicenter clinical study of 111In-DTPA-D-octreotide (MP-1727) in patients with gastrointestinal hormone producing tumors].
- Source :
-
Kaku igaku. The Japanese journal of nuclear medicine [Kaku Igaku] 1995 Nov; Vol. 32 (11), pp. 1269-80. - Publication Year :
- 1995
-
Abstract
- A phase 3 multicenter clinical study was performed to investigate the efficacy, safety and usefulness of MP-1727, a novel tumor imaging agent which binds to somatostatin receptors, in 23 patients with gastrointestinal hormone producing tumor. The efficacy was graded effective or very effective in 16 cases (76.2%) out of 21 cases who could be evaluated. Positive predictive accuracy was 77.8% (7/9) for carcinoids, 100% (5/5) for gastrinomas and 40.0% (2/5) for insulinomas. In three cases, tumor lesions which had been unknown were detected by MP-1727 scintigraphy. The consistent ratio between scintigraphically positive sites and preinjection localizations was 82.0% (41/50 sites) in total. Although adverse drug reactions were observed in two cases, the safety was graded 'not problematic at all' in all of 23 cases. These results show that MP-1727 is a very useful radiopharmaceutical for detection and localization of gastrointestinal hormone producing tumors.
- Subjects :
- Adult
Aged
Carcinoid Tumor diagnostic imaging
Female
Gastrinoma diagnostic imaging
Glucagonoma diagnostic imaging
Humans
Insulinoma diagnostic imaging
Male
Middle Aged
Predictive Value of Tests
Radionuclide Imaging
Sensitivity and Specificity
Somatostatinoma diagnostic imaging
Indium Radioisotopes
Octreotide
Pancreatic Neoplasms diagnostic imaging
Pentetic Acid
Subjects
Details
- Language :
- Japanese
- ISSN :
- 0022-7854
- Volume :
- 32
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Kaku igaku. The Japanese journal of nuclear medicine
- Publication Type :
- Academic Journal
- Accession number :
- 8558797